ArticleOncology letters2017
Azithromycin effectively inhibits tumor angiogenesis by suppressing vascular endothelial growth factor receptor 2-mediated signaling pathways in lung cancer.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Azithromycin Mitigates Experimental Cryptosporidiosis-Driven Ileocecal Adenocarcinoma by Modulating Autophagy, Apoptosis, and PI3K/AKT Signaling.Biomedicines · 2026Article
- Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives.Antibiotics (Basel, Switzerland) · 2024Review
- Neurotoxicity of the antineoplastic drugs: "Doxorubicin" as an example.Journal of molecular histology · 2024Review
- The Role of Natural Extracts in the Management of Infantile Hemangiomas and Vascular Tumors.Pediatric health, medicine and therapeutics · 2024Review
- Azithromycin inhibits glioblastoma angiogenesis in mice via inducing mitochondrial dysfunction and oxidative stress.Cancer chemotherapy and pharmacology · 2023Article
- Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.European journal of medical research · 2023Review
- Angiogenesis-Browning Interplay Mediated by Asprosin-Knockout Contributes to Weight Loss in Mice with Obesity.International journal of molecular sciences · 2022Article
- Environmentally azithromycin pharmaceutical wastewater management and synergetic biocompatible approaches of loaded azithromycin@hematite nanoparticles.Scientific reports · 2022Article
- Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases.Pediatric research · 2022Review
- Review
- Article
- Giant Hepatic Hemangioma Regressed Significantly Without Surgical Management: A Case Report and Literature Review.Frontiers in medicine · 2021Article
- MicroRNA-126: A new and promising player in lung cancer.Oncology letters · 2021Review
- Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment.Acta pharmaceutica Sinica. B · 2020Review
- PAK1-blockers: Potential Therapeutics against COVID-19.Medicine in drug discovery · 2020Review
- ADAMTS-1 inhibits angiogenesis via the PI3K/Akt-eNOS-VEGF pathway in lung cancer cells.Translational cancer research · 2019Article
- Ropivacaine inhibits tumor angiogenesis via sodium-channel-independent mitochondrial dysfunction and oxidative stress.Journal of bioenergetics and biomembranes · 2019Article
- Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer.International journal of molecular sciences · 2019Review
- Utilizing network pharmacology to explore the underlying mechanism ofChinese medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor angiogenesis is essential during lung cancer development and targeting angiogenesis may possess a potential therapeutic value. The present study demonstrates that azithromycin, a Food and Drug Administration-approved antibiotic drug, is a novel tumor angiogenesis inhibitor. Azithromycin inhibits capillary network formation of human lung tumor associated-endothelial cells (HLT-ECs)
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.